Hepatitis B News and Research

Latest Hepatitis B News and Research

Study reveals safety of ConvaTec's advanced antimicrobial dressing

ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced new data showing that AQUACEL(R) Ag, the company's advanced antimicrobial dressing, is safe for use in an MRI environment.

25 Aug 2009

Researchers discover elusive nanoscale movements of ribosomes at work

Researchers at the University of California, Berkeley, have for the first time captured elusive nanoscale movements of ribosomes at work, shedding light on how these cellular factories take in genetic instructions and amino acids to churn out proteins.

24 Aug 2009

The California Chronic Care Coalition launches new website to share information on chronic conditions

The California Chronic Care Coalition (CCCC) continues to advance its work toward meaningful and responsible health care reform with the launching of its consumer website: www.chroniccareca.org. Designed to help build a healthier California, the website is aimed at the more than 16 million Californians with chronic conditions such as Asthma, Diabetes, Alzheimer’s Heart disease, Epilepsy and Multiple Sclerosis.

24 Aug 2009

Safe injection practices for improving safety to be discussed at the Joint Commission Infection Control Conference

Premier healthcare alliance’s Gina Pugliese, vice president of Premier’s Safety Institute, will share insights on safe injection practices to improve patient and worker safety at the Joint Commission Infection Control Conference on August 21 in Crystal City, Va.

21 Aug 2009

Genetic engineering technique used to treat bowel disorders

For the first time, scientists have used a genetically engineered "friendly" bacterium to deliver a therapy.

21 Aug 2009

Seasonal flu vaccinations to cost less in Safeway's U.S. Stores

Safeway Inc. (NYSE:SWY) added to its leadership reputation in health care reform and cost control by offering seasonal flu vaccines in its U.S. stores at a substantial savings compared with the cost of doctor-administered vaccines. The lower cost will help consumers and businesses control health care spending in a challenging economy.

20 Aug 2009

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

U.S. Food and Drug Administration launches new Center for Tobacco Products

The U.S. Food and Drug Administration today launched its new Center for Tobacco Products in an historic effort to curb the hundreds of thousands of deaths caused by those products each year.

19 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.

18 Aug 2009

New findings on how hepatitis C survives for so long in the body

Researchers at the University of Leeds have discovered a previously unknown mechanism that allows the hepatitis C virus (HCV) to remain in the body for decades.

18 Aug 2009

New consortium to tackle African sleeping sickness and Leishmaniasis

A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis, which affect millions of people worldwide.

17 Aug 2009

New biomarker predicts response to hepatitis C treatment

Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference. Duke University Medical Center scientists says the biomarker not only predicts who is most likely to respond to treatment and who isn't, but also may explain why there are such different rates of response among racial and ethnic groups, a phenomenon that has puzzled physicians for years.

16 Aug 2009

New strategy for inhibiting virus replication

Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.

16 Aug 2009

Opinion: U.S. global health strategy; fighting drought

As the U.S. "works on a comprehensive global health strategy," we need to "expand our thinking to encompass holistic solutions that go into improving the health of the world’s poor," Bill Frist, former U.S. Senate Majority leader and current member of the Millennium Challenge Corporation's (MCC) Board of Directors, writes in a Boston Globe opinion piece.

13 Aug 2009

HIV/AIDS funding, treatment standards, empowering women addressed at ICAAP

Funding to fight the spread of HIV/AIDS in Asia and the Pacific has fallen short of the demand, and the majority of available money has missed reaching those at highest risk -- Swarup Sarkar, director of Asia unit for the Global Fund to Fight AIDS, Tuberculosis and Malaria -- said during a session at the 9th International Congress on AIDS in Asia and the Pacific (ICAAP) in Bali, Indonesia, the Jakarta Post reports.

13 Aug 2009

Dynavax announces European development strategy for investigational adult hepatitis B vaccine in Europe

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that it has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAVTM Phase 3 investigational adult hepatitis B vaccine in Europe.

12 Aug 2009